Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,231.94 +46.23 (+3.90%)
Official Closing Price Updated: 7:00 PM EDT, Aug 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know. ↗
Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline. 
Via The Motley Fool
News headline image
Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT? ↗
FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio. 
Via The Motley Fool
Topics ETFs
News headline image
Which iShares Healthcare ETF Is the Better Buy: Diversified IXJ or Biotech-Focused IBB? ↗
IBB delivered 44% returns in one year but swung 40% lower at its worst. IXJ grew steadily with half the volatility and a 1.5% dividend yield. 
Via The Motley Fool
Topics ETFs
Eli Lilly (NYSE:LLY) Shows Strong Growth and Breakout Technical Setup ↗
Via Chartmill
News headline image
Concentrated Pharma Exposure or Broader Global Healthcare? PPH vs. IXJ ↗
The VanEck Pharmaceutical ETF (PPH) gives investors a concentrated way to own major drugmakers, while the iShares Global Healthcare ETF (IXJ) spreads exposure across the wider healthcare sector. The... 
Via The Motley Fool
Topics ETFs
News headline image
Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF? ↗
IHE delivered stronger 5-year returns, but VHT's 0.09% expense ratio and 411 holdings offer broader diversification at lower cost. 
Via The Motley Fool
Topics ETFs
News headline image
Is the iShares Healthcare ETF or the Invesco Nasdaq Biotech ETF the Better Bet for Investors in 2026? ↗
One offers global diversification and higher income; the other delivers focused biotech exposure with lower costs and stronger recent gains. 
Via The Motley Fool
Topics ETFs
News headline image
As Healthcare Rallies Is the Vanguard Health Care ETF of the Invesco Pharmaceuticals ETF the Better Fund for 2026? ↗
PJP surged 45% in one year, but VHT's lower costs and higher dividend yield appeal to long-term income investors seeking broad sector exposure. 
Via The Motley Fool
Topics ETFs
News headline image
Want Income for Life? Here Are 3 Stocks to Buy Now and Never Sell. ↗
A strong yield and an impressive track record of dividend growth aren't enough. The underlying business needs to be enduring. 
Via The Motley Fool
Topics Economy
News headline image
Insider Moves Are Sending Mixed Signals Across the Tech Sector ↗
Broadcom sees insider selling after volatile 2026 trading, while Netskope draws heavy insider buying post-earnings drop and Eli Lilly CEO David Ricks purchases Adobe shares. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
PINK vs. IXJ: Which Health Care ETF Is the Better Buy for Investors? ↗
PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividend yield. 
Via The Motley Fool
Topics ETFs
News headline image
"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks. ↗
Novo Nordisk is also demanding that Eli Lilly pull its ads and pay damages. 
Via The Motley Fool
Topics Lawsuit
News headline image
Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT? ↗
One fund owns the giants of global healthcare, while the other bets on 30 smaller biotech companies. 
Via The Motley Fool
Topics ETFs
News headline image
IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy? ↗
IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-weight approach posted a stronger 1-year return. 
Via The Motley Fool
Topics ETFs
News headline image
1 Unstoppable Vanguard ETF That Could Turn $500 Per Month Into $1 Million ↗
The Vanguard Growth ETF solely focuses on America's largest growth companies. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
Novo Nordisk Sues Eli Lilly Over Alleged Deceptive Weight Loss Drug Advertising ↗
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging false advertising and deceptive marketing for Zepbound and Mounjaro treatments. 
Via Benzinga
Topics Lawsuit
News headline image
Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing ↗
Novo Nordisk is offering an attractive 3.5% yield backed by a business where volume is the new focus. 
Via The Motley Fool
News headline image
Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:CMPS),(NASDAQ:ATAI),(NYSE:JNJ),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV? ↗
FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance. 
Via The Motley Fool
Topics ETFs
News headline image
Eli Lilly (LLY): Buy, Sell, or Hold Post Q1 Earnings?
Eli Lilly has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6.5% to $1,149 p... 
Via StockStory
Topics Stocks
News headline image
Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Merck (NYSE:MRK)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table? ↗
Investors have flocked to Eli Lilly for exposure to the high-growth weight loss drug market. 
Via The Motley Fool
News headline image
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead? ↗
Beam Therapeutics' growing pipeline could reward patient investors. 
Via The Motley Fool
News headline image
For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026? ↗
PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points. 
Via The Motley Fool
Topics ETFs
News headline image
Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026? ↗
IXJ offers broader diversification with 110 holdings and a lower 0.40% expense ratio, while PJP's concentrated U.S. pharma strategy delivered a 44.90% one-year return. 
Via The Motley Fool
Topics ETFs
News headline image
PJP vs. IYH: Which Healthcare ETF Is the Better Buy? ↗
PJP delivered a higher return over the past year -- but IYH charges lower fees and pays a higher dividend yield. 
Via The Motley Fool
Topics ETFs
News headline image
Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market? ↗
It is definitely a strong contender. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Cathie Wood Is Loading Up on This GLP-1 Stock That Has Soared 1,600% Over the Past 10 Years ↗
Maybe you should, too. 
Via The Motley Fool
News headline image
IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now? ↗
BBH offers concentrated exposure to biotech, while IHE provides higher income with lower volatility by focusing on established drugmakers. 
Via The Motley Fool
Topics ETFs
News headline image
IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors? ↗
IHE's top two holdings account for over 43% of its portfolio, while IXJ spreads risk across 110 international stocks. Which concentration strategy fits your risk tolerance? 
Via The Motley Fool
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.